In the present study we investigated the possibility to revert the Th2 polarization of bona fide in vivo primed CEA-specific CD4+ T cells from PC patients by using IL-12 and IL-27 as immunomodulating agents. This evidence concerns the gene CEACAM5 and pachyonychia congenita.